Compare Ginkgo Bioworks Holdings Inc (DNA) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.19 (market cap $763.64M), while YieldMax NVDA Option Income Strategy ETF trades at $12.56 (market cap $1.45B). The key difference: YieldMax NVDA Option Income Strategy ETF is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| DNA | NVDY | |
|---|---|---|
Market Cap | $763.64M | $1.45B |
Volume | 3,204,177 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $15.83 | $17.21 |
52-Week Low | $5.48 | $11.58 |
Typical Hold Time | 7 Days | 43 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.64, down 2.84% on the day amid a bearish technical signal. The fund generates income through options on NVIDIA stock but faces headwinds from declining volatility, which caps upside participation and has led to recent analyst downgrades. Weekly dividend distributions continue, but concerns over net asset value erosion persist.
The outlook for NVDY is cautious, as its high distribution yield comes with structural limitations on capital appreciation. Investment opportunity lies in income generation for risk-tolerant investors, but risks include NAV erosion and dependency on NVIDIA's volatility. Analyst sentiment has shifted to hold, reflecting diminished attractiveness amid lower option premiums.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
